For example, in a phase 1 clinical study of CAR T cell therapy for biliary tract and pancreatic cancers, Her2-targeting CAR-T cells showed peak expansion of 7-fold or less above baseline at day 9 post-injection, dropping thereafter [29]. The gene discussed is ERBB2; the disease is familial pancreatic carcinoma.